Immunotherapy-chemo combo shows promise against stomach cancer
NCT ID NCT04221555
First seen Apr 18, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tested whether adding the immunotherapy drug durvalumab to chemotherapy before and after surgery could help people with a certain type of stomach cancer. The trial included 68 adults with resectable stomach or gastroesophageal junction cancer that was mismatch repair proficient (pMMR). The main goal was to see how many patients had no cancer cells left in their removed tumor tissue after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul, South Korea
Conditions
Explore the condition pages connected to this study.